Leerink Partners Initiates Coverage on Maze Therapeutics (NASDAQ:MAZE)

Research analysts at Leerink Partners initiated coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a report issued on Tuesday,Benzinga reports. The brokerage set an “outperform” rating and a $28.00 price target on the stock. Leerink Partners’ price target would indicate a potential upside of 139.32% from the company’s previous close.

Maze Therapeutics Trading Up 10.7 %

Maze Therapeutics stock opened at $11.70 on Tuesday. Maze Therapeutics has a fifty-two week low of $10.08 and a fifty-two week high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.